The CADTH pCODR Expert Review Committee Process Explained. Comment on Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891-9895

Maureen Trudeau; Brent Fraser

doi:10.3390/curroncol30050380

The CADTH pCODR Expert Review Committee Process Explained. Comment on Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891-9895

Curr Oncol. 2023 May 16;30(5):5047-5049. doi: 10.3390/curroncol30050380.

Authors

Maureen Trudeau¹, Brent Fraser²

Affiliations

¹ Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada.
² CADTH, Ottawa, ON K1S 5S8, Canada.

Abstract

CADTH read with interest the commentary published on 16 December 2022, entitled "Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain" [...].

MeSH terms

Advisory Committees
Breast Neoplasms* / drug therapy
Canada
Female
Humans
Neoadjuvant Therapy
Receptor, ErbB-2
Trastuzumab

Substances

pertuzumab
Trastuzumab
Receptor, ErbB-2